Clinical trials: Advanced
Brucellosis, Zoonotic Disease
Investigation of Fever Suspected as a Zoonosis Using Advanced Diagnostic Technologies
Zoonosis including brucellosis and rickettsial infections are a major contributor to infectious morbidity in southern Israel. The Bedouins, a nomadic tribal population residing in the Negev area are notably exposed to…
- Trial name
- NCT04717622
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Soroka University Medical Center
Stomach Neoplasms
Randomized Controlled Trials on Laparoscopic No. 14v LNS Dissection
The purpose of this study is to explore the short-term, long-term and oncological outcomes of laparoscopic No. 14v lymph node dissection in advanced lower third gastric cancer.
- Trial name
- NCT02789891
- Testing
- D2 lymphadenectomy including No. 14v, lymphadenectomy excluding No. 14v
- Volunteers
- 326 people
- Sponsor
- Fujian Medical University
Parkinson Disease
Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
Assessment of daily maintenance dose of Sifrol®, L-dopa sparing effect, effect on tremor, depression, anhedonia and tolerability
- Trial name
- NCT02248220
- Testing
- Pramipexole
- Volunteers
- 657 people
- Sponsor
- Boehringer Ingelheim
Metastatic Cancer, Prostate Cancer
Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for prostate cancer.
- Trial name
- NCT00002503
- Testing
- strontium chloride Sr 89
- Where
- 21 sites in Belgium, Denmark and 7 more
- Volunteers
- 204 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005088
- Testing
- cisplatin, radiation therapy
- Where
- 258 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Advanced Cancers
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
Primary Objective: Evaluate the agreement between radionuclide ventriculography (RNV) and gated F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in calculating left ventricular ejection…
- Trial name
- NCT00499382
- Testing
- Nuclear Medicine Cardiac Scan, PET/CT Cardiac Scan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer (NSCLC)
Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
The second-line treatment options in clinical practice for immunotherapy progress are complex. Treatment strategies need to be selected based on different progression patterns.
- Trial name
- NCT07596524
- Testing
- Observation
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer, Quality of Life
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
- Conditions
- Cancer, Quality of Life, Anxiety, Depression
- Trial name
- PRISM-AC (NCT03668223)
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 5 sites in United States
- Volunteers
- 269 people
- Sponsor
- Dana-Farber Cancer Institute
PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
The purpose of this study is to provide post-trial access to alpelisib and to assess its long-term safety when administered as a single agent or in combination with other drugs.
- Trial name
- EPIK-RO (NCT07679269)
- Testing
- Alpelisib, Fulvestrant, Trastuzumab
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Cancer
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
This is a study of CS-7017 designed to allow participants who completed participation in a clinical study of CS-7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug.
- Trial name
- NCT00881569
- Testing
- CS-7017
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Daiichi Sankyo
Non-Small Cell Lung Cancer
An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).
This is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the prevalence of EGFR mutations in treatment-naive Russian patients with…
- Trial name
- ORTUS (NCT02321046)
- Where
- 26 sites in Russia
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Breast Cancer
Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00524459
- Testing
- docetaxel, pegylated liposomal doxorubicin hydrochloride, conventional surgery
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Traumatic Brain Injury
Advanced MRI Applications for Mild Traumatic Brain Injury - UCSF
This hypothesis-generating feasibility study compares mTBI Patients and Controls using advanced MRI Applications.
- Trial name
- TBI-2 (NCT02141360)
- Testing
- MRI Diagnostic
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- GE Healthcare
Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL)
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
About this study This is the first study of VTRU200 in people. The main purpose of this study is to find a safe dose of VTRU200 and learn how the medicine behaves in the body.
- Conditions
- Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor Malignancies
- Trial name
- NCT07749976
- Testing
- VTRU200
- Volunteers
- 108 people
- Sponsor
- Vitruviae
A-PRF, ALLOGRAFT
Sticky Bone Compared to A-PRF(Platlet Rich Fibrin) Effect on Alveolar Ridge Preservation
In this research investigators are going to detect the effect of using different type of materials(sticky bone\platlet rich fibrin ) compared to normal healing on the dimensional changes of alveolar crest after single rooted…
- Trial name
- NCT05536492
- Testing
- A-PRF, ALLOGRAFT
- Where
- Palestinian Territories
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Arab American University (Palestine)
Advanced Solid Tumors
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
This is an extension study that will allow participants to continue to receive study therapy when the original studies into which they were enrolled have reached their designated end-dates.
- Trial name
- NCT01178411
- Testing
- Tivantinib, Anti-Cancer Combination Therapy
- Volunteers
- 60 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Advanced Cancer
Study of Erlotinib in Combination With Bortezomib
The goal of this clinical research study is to find the highest tolerable dose of Tarceva (erlotinib hydrochloride) that can safely be given in combination with Velcade (bortezomib).
- Trial name
- NCT00895687
- Testing
- Erlotinib Hydrochloride, Bortezomib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
The purpose of this study is to determine if the combination therapy of Hormone, Paclitaxel and Radiation therapy are effective in treatment of locally advanced prostate cancer
- Trial name
- NCT02911350
- Testing
- Hormone Suppressors, Paclitaxel, Radiation Therapy
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Astrocytoma, IDH-Mutant, Grade 3
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation.
- Trial name
- NCT07215910
- Testing
- Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning
- Where
- 177 sites in United States
- Volunteers
- 408 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.